Skip To Main Content
Kingyin Lee on Muck Rack

Kingyin Lee

As seen in: British Pharmacological Society
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Kingyin

Contact Kingyin, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Evaluation of the Medicines and Healthcare products Regulatory Agency's introduction of a risk‐proportionate approach for clinical trials: An analysis of 4617 applications assessed between September 2023 and August 2024 - Manfrin - British Journal of Clin

|
By Andrea Manfrin, Kingyin Lee, James Pound, Crina Cacou
| British Pharmacological Society
What is already known about this subject Predictable regulatory timelines are critical for researcher and industry activities, particularly in clinical trials. Delays in regulatory activities of clinical trials, which are focused on safety evaluation, can have significant repercussions for researchers, including increased costs, potential impact on trial feasibility and delayed patient treatment access.
Open in Who Shared Issue with article?

Analysis of 4616 clinical trial initial submissions received by the Medicines and Healthcare products Regulatory Agency between February 2019 and October 2023 - Manfrin - British Journal of Clinical Pharmacology - Wiley Online Library

|
By Andrea Manfrin, James Pound, Munir Pirmohamed, Kingyin Lee
| British Pharmacological Society
What is already known about this subject Clinical trials are essential for the advancement of health research and the development of new medicines. Clinical trials contribute substantially to the economy of the UK and to job creation. Having a good understanding of the clinical trials landscape is essential for the development of health, economic and research policies.
Open in Who Shared Issue with article?
See all 2 articles